Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golden Gate phase 3 trial of blinatumomab alternating with low-intensity chemotherapy versus standard chemotherapy in older adults with newly diagnosed Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
MOH_2025-02-16_013918Phase 3Not yet recruiting
- Sponsor
- Amgen
- Start
- Jan 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Amgen. Primary endpoint: Event-free survival. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on MOH_2025-02-16_013918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-16_013918.